We have also demonstrated enhanced expression of ILK, a putative target gene of PPARβ, in high-grade ovarian tumours (Ahmed et al, 2003) and the presence of cell-free irILK in the serum and ascites of ovarian cancer patients (Ahmed et al, 2004). The gene discussed is ILK; the disease is ovarian neoplasm.